Abstracts Archive - Page 1678 of 2425 - ACR Meeting Abstracts

Abstract Number: 3091 • 2015 ACR/ARHP Annual Meeting
A Randomized, Controlled Trial of Pregabalin in Adolescent Patients (12-17 years) with Fibromyalgia
Lesley Arnold¹, Lucinda Bateman², Kenneth N. Schikler³, Tahira Khan⁴, Lynne Pauer⁴, Pritha Bhadra Brown⁵, Marci L. Chew⁴, Andrew Clair⁵ and Joseph Scavone⁴, ¹University of Cincinnati, Cincinnati, OH, ²Bateman Horne Center, Salt Lake City, UT, ³Pediatrics, University of Louisville, Louisville, KY, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., New York, NY
Background/Purpose: :Fibromyalgia (FM) is characterized by chronic widespread pain, sleep disturbance, and fatigue. Pregabalin is approved in the US in adults for the management of…
Abstract Number: 3092 • 2015 ACR/ARHP Annual Meeting
Deficiency of Adenosine Deaminase Type II – Expanding the Clinical Spectrum
Karyl Barron¹, Amanda Ombrello², Deborah Stone², Patrycja Hoffmann², Ivona Aksentijevich^2,3, Qing Zhou², Anne Jones² and Daniel L. Kastner⁴, ¹NIAID/NIH, Bethesda, MD, ²NHGRI/NIH, Bethesda, MD, ³Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase II (DADA2), first described in 2014, is an autosomal recessive disease caused by mutations in CECR1and is characterized by…
Abstract Number: 3093 • 2015 ACR/ARHP Annual Meeting
Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes
Jasmin B. Kuemmerle-Deschner¹, Seza Ozen², Pascal N. Tyrrell³, Isabelle Koné-Paut⁴, Raphaela Goldbach-Mansky⁵, Helen Lachmann⁶, Norbert Blank⁷, Hal M. Hoffman⁸, Elisabeth Weissbarth-Riedel⁹, Boris Huegle¹⁰, Tilmann Kallinich¹¹, Marco Gattorno¹², Ahmet Gul¹³, Nienke M. ter Haar¹⁴, Marlen Oswald¹⁵, Fatma Dedeoglu¹⁶ and Susanne M. Benseler¹⁷, ¹Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ²Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ³Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ⁴Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ⁵Bldg10 rooom 6D47-B, NIH | NIAMS, Bethesda, MD, ⁶UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ⁷Med 5-Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁸University of California at San Diego, San Diego, CA, ⁹Rheumatology, Pediatrics, Universitaetskinderklinik Hamburg, Hamburg, Germany, ¹⁰Pediatric Rheumatology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹¹Charite, University Medicine Berlin, Berlin, Germany, ¹²Pediatry, G. Gaslini Institute, Genova, Italy, ¹³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁴Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵University Hospital Tuebingen, Tuebingen, Germany, ¹⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ¹⁷Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada
Background/Purpose: Cryopyrin Associated Periodic Syndromes (CAPS) are a rare, clinically heterogeneous group of devastating inflammatory illnesses. NLRP3gene gain-of function mutations result in unceasingly raised IL1…
Abstract Number: 3094 • 2015 ACR/ARHP Annual Meeting
Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes
Bengt Hallen¹, Torbjörn Kullenberg¹, Mika Leinonen², Margareta Wiken¹, Raphaela Goldbach-Mansky³ and Hans Olivecrona¹, ¹Swedish Orphan Biovitrum, Stockholm, Sweden, ²4Pharma AB, Stockholm, Sweden, ³Translational Autoinflammatory Diseases Section, NIAMS, NIH, Bethesda, MD
Background/Purpose: Cryopyrin-Associated Periodic Syndromes (CAPS) include a group of rare inherited autoinflammatory diseases consisting of Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome and the most…
Abstract Number: 3095 • 2015 ACR/ARHP Annual Meeting
Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study
Suzanne C. Li¹, Kathryn S. Torok², Sandy D. Hong³, Polly J. Ferguson⁴, C. Egla Rabinovich⁵, Mara L Becker⁶, Fatma Dedeoglu⁷, Maria F. Ibarra⁸, Robert C. Fuhlbrigge^9,10, Katie G. Stewart¹¹, Marilynn G. Punaro¹¹, Thomas Mason II¹², Elena Pope¹³, Ronald Laxer¹⁴, Gloria C. Higgins^15,16 and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁴Dept of Pediatrics--Rheum, University of Iowa, Iowa City, IA, ⁵Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ⁶Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁷Rheumatology, Boston Children's Hospital, Boston, MA, ⁸Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁹Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ¹⁰Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Dermatology, Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology OSU, Nationwide Childrens Hosp, Columbus, OH, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ¹⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease that causes severe morbidity, including growth defects, cosmetic deformities, seizures and arthropathy.…
Abstract Number: 3096 • 2015 ACR/ARHP Annual Meeting
Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels As a Biomarker for IFNg Production in MAS
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello¹, Kathy De Graaf³, Florence Guilhot⁴, Walter Ferlin⁴, Sergio Davì⁵, Grant Schulert⁶, Angelo Ravelli⁵, Alexei A. Grom⁷, Robert Nelson⁴, Cristina de Min⁴ and Fabrizio De Benedetti¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³Novimmune S.A., Geneva, Switzerland, ⁴NovImmune S.A., Geneva, Switzerland, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: A vast body of evidence in animals and humans points to a pivotal pathogenic role of IFNγ, in primary HLH. The role of IFNg…
Abstract Number: 3097 • 2015 ACR/ARHP Annual Meeting
Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma (IFNg) Antibody, in Patients with Hemophagocytic Lymphohistiocytosis (HLH)
Cristina De Min¹, Philippe Jacqmin², Christian Laveille³, Robert Nelson¹, Florence Guilhot¹, Maureen Deehan¹, Marie Kosco-Vilbois¹, Walter Ferlin¹ and Genevieve Lapeyre¹, ¹NovImmune S.A., Geneva, Switzerland, ²SGS Exprimo, Mechelen, Belgium, ³SGS Exprimo NV, Mechelen, Belgium
Background/Purpose: Based on the growing evidence that IFNg plays a pivotal role in HLH, NI-0501, an anti-IFNg monoclonal antibody, is being developed as the first…
Abstract Number: 3098 • 2015 ACR/ARHP Annual Meeting
Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort
Maria DiCicco¹, Frances Humby¹, Stephen Kelly², Rebecca Hands¹, nora ng³, Arti Mahto³, Illias Lazarou³, Vidalba Rocher¹, Lu Zou³, Michele Bombardieri⁴, Christopher Buckley⁵, A.H.M. van der Helm- van Mil⁶, Robert B.M. Landewé⁷, Désirée van der Heijde⁸, Iain B. McInnes⁹, Peter C. Taylor¹⁰ and Costantino Pitzalis¹¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ³William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹⁰Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ¹¹Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
Background/Purpose: The inflammatory cell infiltrate in RA synovium has been recognised to organise into lymphocytic aggregates (Ags) with data to suggest that these structures are…
Abstract Number: 3099 • 2015 ACR/ARHP Annual Meeting
Differential Effects of IL-6 Blockade Tocilizumab and TNF Inhibitors on the Reduced Angiogenesis and Lining Layer Degeneration in Synovial Tissues from Patients with Rheumatoid Arthritis
Hirohata Shunsei¹, Asami Abe^2,3, Akira Murasawa³, Tetsuya Tomita⁴ and Hideki Yoshikawa⁴, ¹Rheumatology and infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatplogy, Niigata Rheumatic Center, Shibata, Japan, ³Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁴Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by hyperplasia of synovial tissues, leading to the destruction of joint structures. TNF inhibitors, including…
Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
Abstract Number: 3101 • 2015 ACR/ARHP Annual Meeting
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Sclerostin Are Related to Joint Destruction in Early Rheumatoid Arthritis Unrelated to Polymorphisms of the Genes
Antonia Boman¹, Heidi Kokkonen², Ewa Berglin¹, Lisbeth Ärlestig¹ and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Department of Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by joint inflammation and destruction of cartilage and bone. The destructive process is related to autoantibodies, genetic polymorphisms involving…
Abstract Number: 3102 • 2015 ACR/ARHP Annual Meeting
Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy
Jon T. Giles¹, S. Louis Bridges Jr.², James R. O'Dell³, Stacey Cofield⁴, George Howard⁵, Jeffrey R. Curtis⁶ and Larry W. Moreland⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Higher levels of circulating adiponectin have been linked to radiographic progression in RA in observational studies, but never studied in the context of early…
Abstract Number: 3103 • 2015 ACR/ARHP Annual Meeting
Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies
Shuichiro Nakabo¹, Koichiro Ohmura¹, Kosaku Murakami¹, Ran Nakashima¹, Moritoshi Furu², Masahiro Ishikawa², Motomu Hashimoto², Yoshitaka Imura¹, Naoichiro Yukawa¹, Hajime Yoshifuji¹, Hiromu Ito², Takao Fujii² and Tsuneyo Mimori^1,2, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Anti-carbamylated protein antibody (anti-CarP) is seen in 45% of rheumatoid arthritis (RA) patients [1]. The precise target antigen (Ag) of anti-CarP had not been…
Abstract Number: 3104 • 2015 ACR/ARHP Annual Meeting
Abnormal DNA Methylation in a Novel PTPN11 Enhancer Increases Destructive Potential of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) and Joint Inflammation
Keisuke Maeshima¹, Stephanie M. Stanford², Deepa Hammaker¹, Cristiano Sacchetti², Rizi Ai³, Vida Zhang⁴, David L. Boyle⁵, Lifan Zeng⁶, German Muench⁷, Gen-Sheng Feng⁸, John Whitaker⁹, Zhong-Yin Zhang⁶, Wei Wang¹⁰, Nunzio Bottini² and Gary S. Firestein⁵, ¹Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁴Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁵Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁶Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, ⁷La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁸Pathology and Division of Biological Sciences, UC San Diego, La Jolla, CA, ⁹Janssen Pharmaceuticals, La Jolla, CA, ¹⁰Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) mediate disease pathogenesis by invading the joint extracellular matrix. The PTPN11 gene, encoding the tyrosine phosphatase SHP-2, is overexpressed…
Abstract Number: 3105 • 2015 ACR/ARHP Annual Meeting
The RA Immune System Recreated in Immunodeficient Mice By Thymic Differentiation from RA Patients’ Hematopoietic Stem Cells Exhibits Marked CD4 T Cell Activation and Differentiation
Robert Winchester¹, Chiara Borsotti², Nichole Danzl², Jon Giles³, Joan M. Bathon⁴ and Megan Sykes², ¹Dept of Pediatrics & Medicine, Columbia University, New York, NY, ²Medicine, Columbia University, New York, NY, ³Rheumatology, Columbia University Medical Center, NY, NY, ⁴Medicine, Columbia University, College, New York, NY
Background/Purpose: We recently reported an advance in modeling the human immune system in mice, (Kalscheuer et al. Sci Transl Med 2012) involving maturation of patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].